Science never stops, and now, with AI, its evolution has sped up dramatically: things humanity had been waiting for centuries are now happening in a mid-sized lab within months or years. I’ve spent years looking at this from the financial side —how a company gets valued, where its cash flow comes from, what happens when technology rewrites the rules— and there’s a question almost nobody in finance dares to ask out loud: if a cure for cancer shows up tomorrow, what does the industry that’s worth trillions treating it today live on?
The business-model problem nobody mentions
It’s not a rhetorical question. The pharmaceutical industry doesn’t bill primarily for curing —it bills, in large part, for managing chronic disease over decades. Diabetes, hypertension, certain cancers: treatments repeated month after month look, financially, more like a subscription than a one-time transaction. A one-shot cure breaks that flow. So the question isn’t just scientific, it’s financial engineering: what replaces that recurring revenue?
What the real evidence already shows
This is where data beats headlines. CAR-T therapy already proved that “curing once” doesn’t mean “billing never again”: there are now six FDA-approved CAR-T products for leukemias, lymphomas, and multiple myeloma, with response rates up to 85% in earlier treatment lines. This year saw the approval of satri-cel, the first CAR-T therapy for a solid tumor —a real milestone, though limited to a specific biomarker, not a universal cure. Its price can exceed US$400,000 per patient, one time. The industry didn’t stop making money by no longer treating chronically; it simply moved the revenue from “monthly subscription” to “single high-margin event.” That’s the real financial risk of AI accelerating cures: not that the business disappears, but that it concentrates into fewer, pricier events, with fewer payers able to front the cost —health systems, insurers, governments.
What nobody tells you: separating signal from noise
When you see an “historic breakthrough” headline, you need to separate signal from noise, and in this field noise is abundant. Russia announced this year the administration of NeoOncovac, a personalized mRNA-based cancer vaccine, to patients with advanced melanoma. It’s real science —they sequence the tumor and design a custom immune response—, but it’s early-stage, applied to roughly 120 patients so far, and it’s therapeutic, not preventive: it doesn’t prevent cancer, it tries to treat it in people who already have it. That’s a genuine signal of progress, not a “cure found” headline. At the other extreme sits the copper-peptide (GHK-Cu) trend: there’s solid evidence in animals —wound healing, tissue repair—, but zero published human studies backing the subcutaneous injections now being sold as anti-aging treatments; and because it’s a naturally occurring molecule, nearly impossible to patent, it’s unlikely any drugmaker will fund the serious clinical trials needed to validate it. It’s the same pattern I described recently about the US$25,000 gene therapy clinic in Próspera, Honduras: when no one certifies the dose or reports adverse events, the absence of regulation isn’t the absence of risk —it’s risk that only the person paying for it carries. That’s where noise beats signal.
A future without disease?
Is it plausible, thanks to AI? With caveats, yes —but not at the scale or timeline the marketing promises. The AI-driven drug discovery market will grow from roughly US$8 billion in 2026 to more than US$34 billion by 2036, and 2026 is, literally, the proof-of-fire year: the first real Phase III results for AI-discovered molecules. The catch is that, so far, those molecules fail in clinical trials at nearly the same rate as traditionally discovered ones —about 90% never reach market, with losses of US$800 million to US$1.4 billion per failed attempt. AI is speeding up the clock; it isn’t yet guaranteeing the outcome.
My take, looking at this as an investor: the real opportunity isn’t betting on this week’s “miracle cure” headline, but understanding that a real cure, when it actually happens, doesn’t destroy value —it reconcentrates it. That changes where capital should look: less at the next viral announcement, more at who has the regulatory, manufacturing, and payment capacity to turn a real scientific advance into an approved, billable treatment. The question I ask myself, and leave with you: when the next “historic breakthrough against cancer” lands in your group chat, do you have the judgment to tell an early-stage trial from an actual cure —or do you share it anyway?
If you want to keep sharpening that judgment every day, the ViSFI Daily Briefing lands for exactly that: separating signal from noise before markets open.